Aventis Pharma Deutschland, Gmbh

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Duetschland Gmbh

Burkhard Haase

Wilfried Schwab

Manfred Schudok

Werner Thorwart

Eckart Bartnik

Klaus-ulrich Weithmann

Bernhard Neises

Gunter Billen

G&uuml;nter Billen

J&uuml;rgen Lindner

Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

Sulfonylaminocarboxylic acids

Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids

The invention relates to a method for finding nucleotide synthesis inhibitors which have a better therapeutic window. An efficacious dose of a nucleotide synthesis inhibitor is administered to a mammal. The concentration of the nucleotide synthesis inhibitor in the blood of the mammal is observed and it is determined whether the nucleotide synthesis inhibitor has a half-life which is shorter than that of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. The invention also relates to a method of using nucleotide synthesis inhibitors in the treatment of immunological diseases.

Method for finding nucleotide synthesis inhibitors having fewer side effects

Substituted diaminocarboxylic acids

N-arylsulfonylamino acid omega-amides

Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and carboxyclic acids

Compounds of formula (I) ##STR1## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

Growing community of inventors

Hofheim, Germany

Burkhard Haase